Sumary of BioNTech to seek approval soon for vaccine for 5- to 11-year olds: Spiegel:
- Frankfurt, September 10 BioNTech is set to request approval across the globe to use its COVID-19 vaccine in children as young as five over the next few weeks and preparations for a launch are on track, the biotech firm’s two top executives told Der Spiegel.
- “Already over the next few weeks we will file the results of our trial in five- to 11-year olds with regulators across the world and will request approval of the vaccine in this age group, also here in Europe,” Chief Medical Officer Oezlem Tuereci told the news weekly.
- Tuereci also told Spiegel that final production steps were being adjusted to bottle a lower-dose pediatric version of its established Comirnaty vaccine.
- The raw trial data was now being prepared for a regulatory filing and “things are looking good, everything is going according to plan”, Chief Executive Ugur Sahin told Der Spiegel.